JP5099570B2 - ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法 - Google Patents

ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法 Download PDF

Info

Publication number
JP5099570B2
JP5099570B2 JP2011530188A JP2011530188A JP5099570B2 JP 5099570 B2 JP5099570 B2 JP 5099570B2 JP 2011530188 A JP2011530188 A JP 2011530188A JP 2011530188 A JP2011530188 A JP 2011530188A JP 5099570 B2 JP5099570 B2 JP 5099570B2
Authority
JP
Japan
Prior art keywords
base sequence
stranded
seq
cells
pluripotent stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011530188A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2012008301A1 (ja
Inventor
典正 三浦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tottori University
Original Assignee
Tottori University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tottori University filed Critical Tottori University
Priority to JP2011530188A priority Critical patent/JP5099570B2/ja
Application granted granted Critical
Publication of JP5099570B2 publication Critical patent/JP5099570B2/ja
Publication of JPWO2012008301A1 publication Critical patent/JPWO2012008301A1/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011530188A 2010-07-12 2011-06-28 ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法 Expired - Fee Related JP5099570B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011530188A JP5099570B2 (ja) 2010-07-12 2011-06-28 ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP2010158194 2010-07-12
JP2010158192 2010-07-12
JP2010158193 2010-07-12
JP2010158192 2010-07-12
JP2010158193 2010-07-12
JP2010158194 2010-07-12
JP2011530188A JP5099570B2 (ja) 2010-07-12 2011-06-28 ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
PCT/JP2011/064846 WO2012008301A1 (ja) 2010-07-12 2011-06-28 ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012202508A Division JP2013046616A (ja) 2010-07-12 2012-09-14 ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法

Publications (2)

Publication Number Publication Date
JP5099570B2 true JP5099570B2 (ja) 2012-12-19
JPWO2012008301A1 JPWO2012008301A1 (ja) 2013-09-09

Family

ID=45469308

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011530188A Expired - Fee Related JP5099570B2 (ja) 2010-07-12 2011-06-28 ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
JP2011530189A Expired - Fee Related JP5099571B2 (ja) 2010-07-12 2011-06-28 ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
JP2012202509A Pending JP2013034479A (ja) 2010-07-12 2012-09-14 ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
JP2012202508A Pending JP2013046616A (ja) 2010-07-12 2012-09-14 ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
JP2013264240A Expired - Fee Related JP5845493B2 (ja) 2010-07-12 2013-12-20 ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2011530189A Expired - Fee Related JP5099571B2 (ja) 2010-07-12 2011-06-28 ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
JP2012202509A Pending JP2013034479A (ja) 2010-07-12 2012-09-14 ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
JP2012202508A Pending JP2013046616A (ja) 2010-07-12 2012-09-14 ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
JP2013264240A Expired - Fee Related JP5845493B2 (ja) 2010-07-12 2013-12-20 ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法

Country Status (5)

Country Link
US (2) US9790491B2 (enExample)
EP (2) EP2594644B1 (enExample)
JP (5) JP5099570B2 (enExample)
CN (2) CN103097535A (enExample)
WO (2) WO2012008302A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012008302A1 (ja) 2010-07-12 2012-01-19 国立大学法人鳥取大学 ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2768945B1 (en) 2011-10-17 2022-01-05 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
EP2844744A2 (en) * 2012-02-22 2015-03-11 Brainstem Biotec Ltd. MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2014012115A2 (en) * 2012-07-13 2014-01-16 Minerva Biotechnologies Corporation Method for inducing cells to less mature state
US10265347B2 (en) 2013-08-29 2019-04-23 Norimasa Miura Biomolecular group related to cell anti-aging
TW201610152A (zh) * 2013-11-22 2016-03-16 國立臺灣大學 微ｒｎａ１４６－ａ及其於診斷、治療及預防小核醣核酸病毒感染之用途及微ｒｎａ１４６－ａ拮抗劑
CN104109670B (zh) * 2014-03-12 2018-01-05 首都医科大学附属北京安定医院 一种双链siRNA分子及其应用
CN106661029B (zh) 2014-06-27 2019-04-05 理森制药股份公司 作为PI3δ和γ蛋白激酶的选择性双重抑制剂的取代色烯衍生物
US10806748B2 (en) 2015-04-24 2020-10-20 The Johns Hopkins University Compositions and methods related to characterizing proviral reservoirs
WO2017073689A1 (ja) * 2015-10-30 2017-05-04 国立大学法人鳥取大学 Ｄｎａ損傷を修復するｒｎａ分子
KR102011336B1 (ko) * 2015-12-31 2019-08-16 인터올리고 주식회사 약물 전달 및 안정화를 위한 복합체 및 그 제조방법
WO2018203553A1 (ja) * 2017-05-02 2018-11-08 株式会社ペジィー・ファーマ 分化細胞の品質改善方法
CA3239665A1 (en) * 2021-12-29 2023-07-06 Norimasa Miura Method for repairing hair cycle-related genes and method for treating hair cycle-related diseases using mir-520d-5p
JP7885560B2 (ja) * 2022-03-31 2026-07-07 株式会社島津製作所 微生物情報の提供方法および微生物検査システム

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112239A1 (ja) * 2005-04-15 2006-10-26 National University Corporation Tottori University ｈＴＥＲＴ発現調節遺伝子
WO2006137514A1 (ja) * 2005-06-23 2006-12-28 Locomogene, Inc. シノビオリンの発現もしくは機能阻害物質を有効成分とする癌治療剤、および癌治療剤のスクリーニング方法
JP2008519606A (ja) * 2004-11-12 2008-06-12 アンビオン インコーポレーティッド ｍｉＲＮＡおよびｍｉＲＮＡ阻害分子に関する方法および組成物
JP2008545406A (ja) * 2005-05-27 2008-12-18 フォンダツィオーネ セントロ サン ラファエレ デル モンテ タボール 遺伝子ベクター
WO2009058413A1 (en) * 2007-10-29 2009-05-07 Shi-Lung Lin Generation of human embryonic stem-like cells using intronic rna
WO2009058907A2 (en) * 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
WO2009057831A1 (ja) * 2007-10-31 2009-05-07 Kyoto University 核初期化方法
WO2009091659A2 (en) * 2008-01-16 2009-07-23 Shi-Lung Lin Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant rna agents
JP2009531019A (ja) * 2006-01-05 2009-09-03 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 固形癌の診断及び治療のためのマイクロｒｎａに基づく方法及び組成物
WO2010058819A1 (ja) * 2008-11-19 2010-05-27 学校法人 慶應義塾 ヒト癌タンパク質ＭＤＭ２とヒト癌抑制タンパク質ｐ５３との相互作用阻害ペプチド及びその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4294482B2 (ja) * 2001-11-15 2009-07-15 協和発酵キリン株式会社 胚性幹細胞から外胚葉系細胞への分化誘導剤、その取得方法及びその用途
AU2003270734A1 (en) 2002-09-16 2004-04-30 University Of Southern California Rna-mediated gene modulation
KR20050115231A (ko) 2003-02-10 2005-12-07 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 포유동물 세포의 조절
MX2007009417A (es) 2005-02-04 2007-08-17 Univ Auburn Sistema de suministro de farmaco de contacto.
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
KR101532442B1 (ko) 2007-12-10 2015-06-29 고쿠리츠 다이가쿠 호진 교토 다이가쿠 효율적인 핵 초기화 방법
US9006191B2 (en) * 2007-12-27 2015-04-14 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering RNA
CN101333524B (zh) * 2008-06-25 2010-06-02 中山大学 一个小分子非编码RNA基因hsa-miR-101及其抗肿瘤用途
CN101392251B (zh) * 2008-11-03 2015-07-22 清华大学深圳研究生院 能诱导干细胞向成骨细胞分化的微小rna及其应用
WO2012008302A1 (ja) 2010-07-12 2012-01-19 国立大学法人鳥取大学 ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519606A (ja) * 2004-11-12 2008-06-12 アンビオン インコーポレーティッド ｍｉＲＮＡおよびｍｉＲＮＡ阻害分子に関する方法および組成物
WO2006112239A1 (ja) * 2005-04-15 2006-10-26 National University Corporation Tottori University ｈＴＥＲＴ発現調節遺伝子
JP2008545406A (ja) * 2005-05-27 2008-12-18 フォンダツィオーネ セントロ サン ラファエレ デル モンテ タボール 遺伝子ベクター
WO2006137514A1 (ja) * 2005-06-23 2006-12-28 Locomogene, Inc. シノビオリンの発現もしくは機能阻害物質を有効成分とする癌治療剤、および癌治療剤のスクリーニング方法
JP2009531019A (ja) * 2006-01-05 2009-09-03 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 固形癌の診断及び治療のためのマイクロｒｎａに基づく方法及び組成物
WO2009058413A1 (en) * 2007-10-29 2009-05-07 Shi-Lung Lin Generation of human embryonic stem-like cells using intronic rna
WO2009058907A2 (en) * 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
WO2009057831A1 (ja) * 2007-10-31 2009-05-07 Kyoto University 核初期化方法
WO2009091659A2 (en) * 2008-01-16 2009-07-23 Shi-Lung Lin Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant rna agents
WO2010058819A1 (ja) * 2008-11-19 2010-05-27 学校法人 慶應義塾 ヒト癌タンパク質ＭＤＭ２とヒト癌抑制タンパク質ｐ５３との相互作用阻害ペプチド及びその使用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6011055351; 臨床薬理 Ｖｏｌ．４０，　Ｎｏ．Ｓｕｐｐｌｅｍｅｎｔ, 20091118, ｐ．Ｓ１９０ *
JPN6011055352; 程　久美子　他: ＲＮＡｉ実験なるほどＱ＆Ａ ｐ．８８-９６, 20061001, 羊土社 *
JPN6011055354; 臨床薬理 Ｖｏｌ．３８，　Ｎｏ．Ｓｕｐｐｌｅｍｅｎｔ, 20071115, ｐ．Ｓ２９５ *
JPN6011055356; Ｃｅｌｌ Ｖｏｌ．１３１，　Ｎｏ．５, 2007, ｐ．８６１-８７２ *
JPN6012014227; Ｎａｔｕｒｅ　Ｍｅｔｈｏｄｓ Ｖｏｌ．２，　Ｎｏ．８, 2005, Ａｐｐｌｉｃａｔｉｏｎ　Ｎｏｔｅｓ *
JPN6012014228; Ｍｏｌ．Ｂｉｏｔｅｃｈｎｏｌ． Ｖｏｌ．４３，　Ｎｏ．３, 2009, ｐ．２００-２１１ *
JPN6012014230; Ｊ．Ｍｏｌ．Ｂｉｏｌ． Ｖｏｌ．３４８，　Ｎｏ．５, 2005, ｐ．８８３-８９３ *

Also Published As

Publication number Publication date
JP2014097059A (ja) 2014-05-29
EP2594643A4 (en) 2014-12-24
CN103097535A (zh) 2013-05-08
JP5099571B2 (ja) 2012-12-19
EP2594644A4 (en) 2014-12-24
JP2013034479A (ja) 2013-02-21
US20130184335A1 (en) 2013-07-18
US20130190389A1 (en) 2013-07-25
US9476041B2 (en) 2016-10-25
JPWO2012008302A1 (ja) 2013-09-09
EP2594643A1 (en) 2013-05-22
JPWO2012008301A1 (ja) 2013-09-09
EP2594644A1 (en) 2013-05-22
EP2594644B1 (en) 2016-08-10
JP2013046616A (ja) 2013-03-07
WO2012008301A1 (ja) 2012-01-19
US9790491B2 (en) 2017-10-17
WO2012008302A1 (ja) 2012-01-19
CN103189511B (zh) 2016-10-12
JP5845493B2 (ja) 2016-01-20
CN103189511A (zh) 2013-07-03
EP2594643B1 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
JP5845493B2 (ja) ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
AU2024201552B2 (en) Compositions and methods for reprogramming somatic cells into induced vasculogenic cells
JP2021164462A (ja) 修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現
EP3040414B1 (en) Biomolecular group related to cell anti-aging
CA2930973C (en) Short-acting RNA compositions of C/EBP ALPHA and methods of use
US12281310B2 (en) Use of trinucleotide repeat RNAs to treat cancer
US20250101433A1 (en) Means and methods for reducing tumorigenicity of cancer stem cells
WO2014097875A1 (ja) 新規の脱分化誘導方法を用いた多能性幹細胞化
WO2015042720A1 (en) Novel lincrna and interfering nucleic acid molecules, compositions and methods and uses thereof for regulating angiogenesis and related conditions
AU2011256098A1 (en) Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas
KR101197627B1 (ko) Ｈｐｖ 감염과 관련된 암의 치료용 조성물
US9045752B2 (en) NKX3-1 saRNA and KLF4 saRNA and uses thereof
Moriconi  Caveolin-1: a mediator of Glioblastoma cell invasion and an independent negative biomarker of Glioblastoma patient survival

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120817

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120914

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151005

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees